Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Markets expect ...

Online vehicle auction company Copart (NASDAQ:CPRT) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

Genmab A/S announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

In terms of performance, Aditya Birla Real Estate ... In the realm of technical analysis for our subject stock, the moving averages present a detailed picture. Over a short span of 5 days, the ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

which tends to hurt stock performance. In recent months, the strategy was more exposed to the Yield factor compared with its Morningstar Category peers as well. This strategy has had lower ...